变应性鼻炎患者血清miR-19b和SOCS-1 mRNA表达水平与临床症状的相关性

IF 3 3区 医学 Q2 ALLERGY
Journal of Asthma and Allergy Pub Date : 2025-04-22 eCollection Date: 2025-01-01 DOI:10.2147/JAA.S518177
Zhaopeng Kang, Lingling Di, Yi Liu, Wei Qu, Yi Zeng, Xue Lu, Lixin Wang
{"title":"变应性鼻炎患者血清miR-19b和SOCS-1 mRNA表达水平与临床症状的相关性","authors":"Zhaopeng Kang, Lingling Di, Yi Liu, Wei Qu, Yi Zeng, Xue Lu, Lixin Wang","doi":"10.2147/JAA.S518177","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the correlation between the expression levels of microRNA-19b (miR-19b) and suppressor of cytokine signaling 1 messenger RNA (SOCS-1 mRNA) in the serum of patients with allergic rhinitis (AR) and clinical symptoms.</p><p><strong>Methods: </strong>This prospective study included a total of 86 patients with allergic rhinitis who were admitted to the People's Hospital Affiliated to Hubei University of Medicine from January 2022 to January 2023. Seventy healthy individuals were included in the control group. The case group was further divided into a mild group (n=45) and a moderate to severe group (n=41) according to the severity of AR. The expression levels of miR-19b and SOCS-1 mRNA in serum samples of the two groups were detected and compared using real-time fluorescence quantitative polymerase chain reaction (qRT-PCR) technique. The receiver operating characteristic (ROC) curve and the area under the curve (AUC) were utilized to evaluate the predictive value of miR-19b and SOCS-1 levels for the severity of AR.</p><p><strong>Results: </strong>The expression level of miR-19b in the serum of the case group was 1.52±0.36, significantly higher than that of the control group (1.02±0.24, P<0.05). Logistic regression analysis indicated that low levels of serum miR-19b and SOCS-1 mRNA were independent risk factors for moderate to severe AR, with an odds ratio (OR) of 3.575 (95% CI: 1.572-8.133, P<0.001) for miR-19b and 3.725 (95% CI: 1.637-8.473, P<0.001) for SOCS-1 mRNA. ROC curve analysis demonstrated that the levels of serum miR-19b and SOCS-1 mRNA had high accuracy in predicting moderate to severe AR, with AUC values of 0.879 (95% CI: 0.791-0.940) and 0.795 (95% CI: 0.694-0.875), respectively. When combined for prediction, the efficacy was significantly higher than that of individual detection, with an AUC value of 0.923 (95% CI: 0.856-0.967), Z=3.261, P<0.01.</p><p><strong>Conclusion: </strong>The expression levels of serum miR-19b and SOCS-1 mRNA are closely related to the severity of clinical symptoms in patients with AR and may serve as new biomarkers for evaluating the condition of AR and guiding treatment.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"619-627"},"PeriodicalIF":3.0000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12032965/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Correlation Between the Expression Levels of Serum miR-19b and SOCS-1 mRNA and Clinical Symptoms in Patients with Allergic Rhinitis.\",\"authors\":\"Zhaopeng Kang, Lingling Di, Yi Liu, Wei Qu, Yi Zeng, Xue Lu, Lixin Wang\",\"doi\":\"10.2147/JAA.S518177\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To investigate the correlation between the expression levels of microRNA-19b (miR-19b) and suppressor of cytokine signaling 1 messenger RNA (SOCS-1 mRNA) in the serum of patients with allergic rhinitis (AR) and clinical symptoms.</p><p><strong>Methods: </strong>This prospective study included a total of 86 patients with allergic rhinitis who were admitted to the People's Hospital Affiliated to Hubei University of Medicine from January 2022 to January 2023. Seventy healthy individuals were included in the control group. The case group was further divided into a mild group (n=45) and a moderate to severe group (n=41) according to the severity of AR. The expression levels of miR-19b and SOCS-1 mRNA in serum samples of the two groups were detected and compared using real-time fluorescence quantitative polymerase chain reaction (qRT-PCR) technique. The receiver operating characteristic (ROC) curve and the area under the curve (AUC) were utilized to evaluate the predictive value of miR-19b and SOCS-1 levels for the severity of AR.</p><p><strong>Results: </strong>The expression level of miR-19b in the serum of the case group was 1.52±0.36, significantly higher than that of the control group (1.02±0.24, P<0.05). Logistic regression analysis indicated that low levels of serum miR-19b and SOCS-1 mRNA were independent risk factors for moderate to severe AR, with an odds ratio (OR) of 3.575 (95% CI: 1.572-8.133, P<0.001) for miR-19b and 3.725 (95% CI: 1.637-8.473, P<0.001) for SOCS-1 mRNA. ROC curve analysis demonstrated that the levels of serum miR-19b and SOCS-1 mRNA had high accuracy in predicting moderate to severe AR, with AUC values of 0.879 (95% CI: 0.791-0.940) and 0.795 (95% CI: 0.694-0.875), respectively. When combined for prediction, the efficacy was significantly higher than that of individual detection, with an AUC value of 0.923 (95% CI: 0.856-0.967), Z=3.261, P<0.01.</p><p><strong>Conclusion: </strong>The expression levels of serum miR-19b and SOCS-1 mRNA are closely related to the severity of clinical symptoms in patients with AR and may serve as new biomarkers for evaluating the condition of AR and guiding treatment.</p>\",\"PeriodicalId\":15079,\"journal\":{\"name\":\"Journal of Asthma and Allergy\",\"volume\":\"18 \",\"pages\":\"619-627\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-04-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12032965/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Asthma and Allergy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/JAA.S518177\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Asthma and Allergy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JAA.S518177","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:探讨变应性鼻炎(AR)患者血清中microRNA-19b (miR-19b)和细胞因子信号传导抑制因子1信使RNA (SOCS-1 mRNA)的表达水平与临床症状的相关性。方法:本前瞻性研究纳入2022年1月至2023年1月湖北医学院附属人民医院收治的86例变应性鼻炎患者。70名健康个体被纳入对照组。根据AR的严重程度将病例组进一步分为轻度组(n=45)和中至重度组(n=41),采用实时荧光定量聚合酶链反应(qRT-PCR)技术检测两组血清样本中miR-19b和SOCS-1 mRNA的表达水平并进行比较。采用受试者工作特征曲线(ROC)和曲线下面积(AUC)评价miR-19b和SOCS-1水平对急性呼吸综合征严重程度的预测价值。结果:病例组血清miR-19b表达水平为1.52±0.36,显著高于对照组(1.02±0.24),p < 0.05。血清miR-19b和SOCS-1 mRNA的表达水平与AR患者临床症状的严重程度密切相关,可作为评估AR病情和指导治疗的新的生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

The Correlation Between the Expression Levels of Serum miR-19b and SOCS-1 mRNA and Clinical Symptoms in Patients with Allergic Rhinitis.

The Correlation Between the Expression Levels of Serum miR-19b and SOCS-1 mRNA and Clinical Symptoms in Patients with Allergic Rhinitis.

The Correlation Between the Expression Levels of Serum miR-19b and SOCS-1 mRNA and Clinical Symptoms in Patients with Allergic Rhinitis.

Objective: To investigate the correlation between the expression levels of microRNA-19b (miR-19b) and suppressor of cytokine signaling 1 messenger RNA (SOCS-1 mRNA) in the serum of patients with allergic rhinitis (AR) and clinical symptoms.

Methods: This prospective study included a total of 86 patients with allergic rhinitis who were admitted to the People's Hospital Affiliated to Hubei University of Medicine from January 2022 to January 2023. Seventy healthy individuals were included in the control group. The case group was further divided into a mild group (n=45) and a moderate to severe group (n=41) according to the severity of AR. The expression levels of miR-19b and SOCS-1 mRNA in serum samples of the two groups were detected and compared using real-time fluorescence quantitative polymerase chain reaction (qRT-PCR) technique. The receiver operating characteristic (ROC) curve and the area under the curve (AUC) were utilized to evaluate the predictive value of miR-19b and SOCS-1 levels for the severity of AR.

Results: The expression level of miR-19b in the serum of the case group was 1.52±0.36, significantly higher than that of the control group (1.02±0.24, P<0.05). Logistic regression analysis indicated that low levels of serum miR-19b and SOCS-1 mRNA were independent risk factors for moderate to severe AR, with an odds ratio (OR) of 3.575 (95% CI: 1.572-8.133, P<0.001) for miR-19b and 3.725 (95% CI: 1.637-8.473, P<0.001) for SOCS-1 mRNA. ROC curve analysis demonstrated that the levels of serum miR-19b and SOCS-1 mRNA had high accuracy in predicting moderate to severe AR, with AUC values of 0.879 (95% CI: 0.791-0.940) and 0.795 (95% CI: 0.694-0.875), respectively. When combined for prediction, the efficacy was significantly higher than that of individual detection, with an AUC value of 0.923 (95% CI: 0.856-0.967), Z=3.261, P<0.01.

Conclusion: The expression levels of serum miR-19b and SOCS-1 mRNA are closely related to the severity of clinical symptoms in patients with AR and may serve as new biomarkers for evaluating the condition of AR and guiding treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Asthma and Allergy
Journal of Asthma and Allergy Medicine-Immunology and Allergy
CiteScore
5.30
自引率
6.20%
发文量
185
审稿时长
16 weeks
期刊介绍: An international, peer-reviewed journal publishing original research, reports, editorials and commentaries on the following topics: Asthma; Pulmonary physiology; Asthma related clinical health; Clinical immunology and the immunological basis of disease; Pharmacological interventions and new therapies. Although the main focus of the journal will be to publish research and clinical results in humans, preclinical, animal and in vitro studies will be published where they shed light on disease processes and potential new therapies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信